Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch

Vaccine

Volumn 24, Issue 13, 2006, Pages 2275-2282

  Ghochikyan, Anahit ^a   Mkrtichyan, Mikayel ^a   Petrushina, Irina ^b   Movsesyan, Nina ^a   Karapetyan, Adrine ^a   Cribbs, David H ^b   Agadjanyan, Michael G ^a,b  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease (AD); Epitope vaccine immunization; Th1 and Th2 adjuvants

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-42]; B LYMPHOCYTE ANTIGEN; EPITOPE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOLOGICAL ADJUVANT; PADRE ANTIGEN; QUIL A; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; INJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; BRAIN; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SAPONINS; TH1 CELLS; TH2 CELLS;

EID: 33344460820     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.11.039     Document Type: Article

References (48)

1. D.L. Price, and S.S. Sisodia Cellular and molecular biology of Alzheimer's disease and animal models Annu Rev Med 45 1994 435 446
2. J.A. Hardy, and G.A. Higgins A Alzheimer's disease: the amyloid cascade hypothesis Science 256 1992 184 185
3. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 2002 353 356
4. D. Selkoe Amyloid protein and Alzheimer's disease Sci Am 265 5 1991 68 71 74-6, 78
5. D.J. Selkoe Alzheimer's disease: a central role for amyloid J Neuropath Exp Neurol 53 5 1994 438 447
6. W.P. Esler, and M.S. Wolfe A portrait of Alzheimer Secretases-new features and familiar faces Science 293 2001 1449 1454
7. L. Mucke, E. Masliah, G.Q. Yu, M. Mallory, E.M. Rockenstein, and G. Tatsuno High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J Neurosci 20 11 2000 4050 4058
8. Y. Matsuoka, M. Picciano, B. Malester, J. LaFrancois, C. Zehr, and J.M. Daeschner Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease Am J Pathol 158 4 2001 1345 1354
9. J.C. Dodart, C. Mathis, K.R. Bales, and S.M. Paul Does my mouse have Alzheimer's disease? Genes Brain Behav 1 3 2002 142 155
10. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse (see comments) Nature 400 6740 1999 173 177
11. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, and J. Hardy A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 6815 2000 982 985
12. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, and S.D. Schmidt A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 2000 979 982
13. G. Chen, K.S. Chen, J. Knox, J. Inglis, A. Bernard, and S.J. Martin A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease Nature 408 2000 975 979
14. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 8 2000 916 919
15. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci USA 98 15 2001 8850 8855
16. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, and V. Betts Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo Nat Med 11 6 2005 556 561
17. S. Oddo, L. Billings, J.P. Kesslak, D.H. Cribbs, and F.M. LaFerla Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 43 3 2004 321 332
18. D.H. Cribbs, and M.G. Agadjanyan Immunotherapy for Alzheimer's disease: potential problems and possible solutions Curr Immunol Rev 1 2 2005 95
19. D.H. Cribbs, A. Ghochikyan, M. Tran, V. Vasilevko, I. Petrushina, and N. Sadzikava Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid Int Immunol 15 4 2003 505 514
20. P.C. Charles, K.S. Weber, B. Cipriani, and C.F. Brosnan Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias J Neuroimmunol 100 1-2 1999 64 73
21. D. Steinberg Companies halt first Alzheimer's vaccine trial Scientist 2002 22 23
22. K. Birmingham, and S. Frantz Set back Alzheimer vaccine studies Nat Med 8 3 2002 199 200
23. D. Schenk Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning Nat Rev Neurosci 3 10 2002 824 828
24. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, and B. Muller-Tillmanns Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 4 2003 547 554
25. J.M. Orgogozo, S. Gilman, J.M. Dartigues, B. Laurent, M. Puel, and L.C. Kirby Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 1 2003 46 54
26. K. Senior Dosing in phase II trial of Alzheimer's vaccine suspended Lancet Neurol 1 1 2002 3
27. M. Lee, F. Bard, K. Johnson-Wood, C. Lee, K. Hu, and S.G. Griffith Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies Ann Neurol 58 3 2005 430 435
28. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, and N.C. Fox Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 9 2005 1553 1562
29. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, and L. Jenkins Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology 64 9 2005 1563 1572
30. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report Nat Med 9 4 2003 448 452
31. I. Ferrer, M.B. Rovira, Guerra MLS, M.J. Rey, and F. Costa-Jussa Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease Brain Pathol 14 1 2004 11 20
32. E. Masliah, L. Hansen, A. Adame, L. Crews, F. Bard, and C. Lee Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 64 1 2005 129 131
33. A.J. Bayer, R. Bullock, R.W. Jones, D. Wilkinson, K.R. Paterson, and L. Jenkins Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD Neurology 64 1 2005 94 101
34. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, and D. Games Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc Natl Acad Sci USA 100 4 2003 2023 2028
35. B.J. Bacskai, S.T. Kajdasz, M.E. McLellan, D. Games, P. Seubert, and D. Schenk Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy J Neurosci 22 18 2002 7873 7878
36. M.G. Agadjanyan, A. Ghochikyan, I. Petrushina, V. Vasilevko, N. Movsesyan, and M. Mkrtichyan Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide J Immunol 174 3 2005 1580 1586
37. P.O. Livingston, S. Adluri, F. Helling, T.J. Yao, C.R. Kensil, and M.J. Newman Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma Vaccine 12 14 1994 1275 1280
38. C.R. Kensil, and R. Kammer QS-21: a water-soluble triterpene glycoside adjuvant Expert Opin Investig Drugs 7 9 1998 1475 1482
39. R.K. Gupta, and G.R. Siber Adjuvants for human vaccines - current status, problems and future prospects Vaccine 13 14 1995 1263 1276
40. I. Petrushina, M. Tran, N. Sadzikava, A. Ghochikyan, V. Vasilevko, and M.G. Agadjanyan Importance of IgG2c isotype in the immune response to b-amyloid in APP/Tg mice Neurosci Lett 338 2003 5 8
41. O. Kashala, R. Amador, M.V. Valero, A. Moreno, A. Barbosa, and B. Nickel Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21 Vaccine 20 17-18 2002 2263 2277
42. P. Panina-Bordignon, A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells Eur J Immunol 19 12 1989 2237 2242
43. S.K. Chai, P. Clavijo, J.P. Tam, and F. Zavala Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes J Immunol 149 7 1992 2385 2390
44. F.D. Finkelman, J. Holmes, I.M. Katona, J.F. Urban, M.P. Beckmann, and L.S. Park Lymphokine control of in vivo immunoglobulin isotype selection Ann Rev Immunol 8 1990 303 333
45. C.M. Snapper, and W.E. Paul Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production Science 236 4804 1987 944 947
46. J. Hasbold, J.S. Hong, M.R. Kehry, and P.D. Hodgkin Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a J Immunol 163 8 1999 4175 4481
47. R.L. Coffman, H.F. Savelkoul, and D.A. Lebman Cytokine regulation of immunoglobulin isotype switching and expression Semin Immunol 1 1 1989 55 63
48. T.R. Mosmann, and R.L. Coffman TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties Annu Rev Immunol 7 1989 145 173